Login
From:
Drug Discovery and Development
(Uncensored)
subscribe
Eli Lilly acquires Verve Therapeutics in $1.3 billion deal, validating gene editing for heart disease
https://www.drugdiscoverytrends.com/eli-lilly-acquires-verve-therapeutics-in-1-3-billion-deal-validating-gene-editing-for-heart-disease/
links
backlinks
Tagged with:
acquisition
cardiovascular disease
eli lilly
1.3 billion
base editing
contingent value right
Eli Lilly and Co. has agreed to buy Verve Therapeutics Inc. for up to $1.3 billion, in a move that bolsters Lilly's push into gene editing for cardiovascular conditions and signals renewed confidence in the sector.
Roast topics
Find topics
Find it!
